U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Clinical Guidelines Centre (UK). Stable Angina: Methods, Evidence & Guidance [Internet]. London: Royal College of Physicians (UK); 2011 Jul. (NICE Clinical Guidelines, No. 126.)

  • Update information August 2016: NICE added a footnote to recommendations 1.4.11 and 1.4.12 covering the new advice from the Medicines and Healthcare products Regulatory Agency (MHRA) about safety concerns related to ivabradine (June 2014 and December 2014) and nicorandil (January 2016).

Update information August 2016: NICE added a footnote to recommendations 1.4.11 and 1.4.12 covering the new advice from the Medicines and Healthcare products Regulatory Agency (MHRA) about safety concerns related to ivabradine (June 2014 and December 2014) and nicorandil (January 2016).

Cover of Stable Angina

Stable Angina: Methods, Evidence & Guidance [Internet].

Show details

Appendix FForest Plots

Ivabradine for stable angina

Nicorandil versus Placebo for stable angina

Medical versus CABG for stable angina

4. Single vessel disease- medium term follow-up (2–4 years)

4.1 Death

4.2 Stroke

4.3 MI

4.4 Non protocol revascularisation

4.5 Free of angina

6. Left main stem disease- Medium term follow-up (2 to 4 years)

6.1 Death

7. Left main stem disease- Long term follow-up (>4 years)

7.1 Death

7.2 MI

8. Left anterior descending artery - Long term follow-up (>4 years)

8.1 Death

Medical versus PCI for stable angina

Medical versus PCI or CABG for stable angina

1. Multivessel disease- short term follow-up (1 year)

1.1 Death

1.2 MI

1.3 Non protocol revascularisation

2. Multi vessel disease- medium term follow-up ( 2 to 4 years)

2.1 Death

2.2 Non protocol revascularisation

2.3 Non fatal MI

4. Angiography prior randomisation - Multivessel disease short term

4.1 Death

4.2 MI

4.3 Non protocol revascularisation

5. Angiography prior randomisation- Multivessel disease medium term follow-up

5.1 Death

5.2 Non protocol revascularisation

PCI versus CABG for Stable angina

1. Multi vessel disease - Immediate follow-up

1.1 Stroke

5. Single vessel disease - Short term follow-up (1 yr)

5.1 Death (all causes)

5.2 MI

5.3 Free of angina

8. Left main coronary disease - Short term follow-up (1 yr)

8.1 Death

8.2 non fatal MI

8.3 Stroke

8.4 Repeat revascularisation

8.5 Cardiac death

Rehabilitation for stable angina

2. Stress management + exercise vs. routine care control (8 weeks)

2.1 Frequency of angina (average no. of daily attacks)

2.2 Duration of angina (min)

3. Stress management + exercise vs. routine care (8 weeks) (change scores)

3.1 Frequency of angina

3.2 Duration of angina

6. Nurse led cardiac rehab vs. routine care (6 months)

6.1 Walking performance (Jenkins activity checklist for walking)

8. Angina Plan vs. Education session (6 months) ( all of the outcomes below report change scores)

8.1 Anxiety (HAD scale) (scores between 8 and 10 indicate bordeline presence of anxiety)

8.2 Depression (HAD scale) (scores between 8 and 10 indicate borderline presence of depression)

8.3 Angina attacks per week

8.4 Mean pain score

8.5 Mean duration of pain

8.6 Physical limitation (Seattle Angina questionnaire) (0 to 100 scale with higher scores indicating better functioning)

8.7 Angina stability (Seattle Angina questionnaire)(0 to 100 scale with higher scores indicating better functioning)

8.8 Angina frequency (Seattle Angina questionnaire)(0 to 100 scale with higher scores indicating better functioning)

8.9 Treatment satisfaction (Seattle Angina questionnaire)(0 to 100 scale with higher scores indicating better functioning)

8.10 Disease perception (Seattle Angina questionnaire)(0 to 100 scale with higher scores indicating better functioning)

8.11 Misconceptions/knowledge

8.12 CLASP angina

8.13 Physical function (SF-36) (scores between 0 to 100 with higher scores representing better health status)

8.14 Energy and and vitality (SF-36)(scores between 0 to 100 with higher scores representing better health status)

8.15 Pain (SF-36)(scores between 0 to 100 with higher scores representing better health status)

8.16 GH perception (SF-36)(scores between 0 to 100 with higher scores representing better health status)

8.17 Change in health (SF-36)(scores between 0 to 100 with higher scores representing better health status)

8.18 SEI QOL- DW QOL score (overall score ranging from 0–100 with higher scores reflecting better quality of life)

Lifestyle factors for stable angina

2. Fish advice (dietary fish advice + fish oil capsule) vs. Fruit advice (Mortality ascertained after 3 to 9 yrs)

2.1 All death

2.2 Cardiac death

2.3 Sudden death

3. Fish advice (dietary fish advice+ fish oil capsule) vs. Fish +Fruit advice (Mortality ascertained after 3 to 9 yrs)

3.1 All death

3.2 Cardiac death

3.3 Sudden death

4. Fish advice (dietary fish advice + fish oil capsule) vs. Sensible eating (non -specific advice) (Mortality ascertained after 3 to 9 yrs)

4.1 All deaths

4.2 Cardiac death

4.3 Sudden death

Pain interventions for stable/refractory angina

Drugs versus Placebo or other drug for Cardiac Syndrome X

4. beta blockers vs calcium channel blockers in patients with pressure-rate product variation <1050

4.1 exercise duration (sec)

5. beta blockers vs calcium channel blockers in patients with pressure-rate product variation >1050

5.1 exercise duration (sec)

9. Aminophylline vs Nitroglycerine

9.1 Time to 1mm ST depression

Copyright © 2011, National Clinical Guidelines Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of the National Clinical Guidelines Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

Bookshelf ID: NBK83585